Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies

EHA 2025

12 - 15 Jun 2025

Published: 27 Jun 2025

Views: 2

Rating:

Save

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany

Dr Moritz Fürstenau speaks to ecancer about the phase 3 GAIA/CLL13 trial.

This trial assesses various venetoclax-based combinations for chronic lymphocytic leukaemia (CLL).

The study compares venetoclax obinutuzumab and other combinations to standard chemo immunotherapy, focusing on minimal residual disease rates and progression-free survival.

Results show significant improvements with venetoclax obinutuzumab and the triple combination, but concerns about quality of life and potential toxicities arise, impacting its first-line use.

Related Videos

The combination of acimtamig and AlloNK® therapy demonstrates promising...

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA

The combination of acimtamig and AlloNK® therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

$POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )$

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

The need for improved healthcare infrastructure for extranodal NK/T-cell...

Dr Fabiola Valvert - INCAN, Guatemala City, Guatemala

The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America ( Dr Fabiola Valvert - INCAN, Guatemala City, Guatemala )

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r...

Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL ( Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA )

30 minute infusion of isatuximab shows potential in newly diagnosed multiple...

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Optimising benefit-risk and minimising impact on quality of life with BCMA...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

More from ecancer